Á¦ ¸ñ    CYVRNivKQguOsv
ÀÌ ¸§    Alexandra ³¯ Â¥    2018/06/28 Á¶ ȸ    4


Insufficient funds diabeteshealth.com The new drugs are born out of a better understanding of the molecular changes that fuel cancer growth. For example, an estimated 50 to 60 percent of melanoma patients have a specific genetic mutation. Zelboraf and Tafinlar target these people. By testing such treatments only on people with a specific mutation, researchers can work out more quickly, and with fewer patients, if a treatment is effective.